Europe has been adopting the latest healthcare system to provide better care and treatment for its patients. As a result, the region has one of the finest healthcare systems in the world. The Europe chronic idiopathic constipation drug market was valued at $XX million in the year 2017. The market is further predicted to rise at a CAGR of 8.96% during the forecast years of 2018-2026.

EUROPE CHRONIC IDIOPATHIC CONSTIPATION DRUG MARKET FORECAST 2018-2026

Europe Chronic Idiopathic Constipation Drug Market by Drug Type (Lubiprostone, Linaclotide & Others) by Prescription (Prescribed Drugs, Over the Counter Drugs) by Geography

Request free sample

Report Summary

Europe has been adopting the latest healthcare system to provide better care and treatment for its patients. As a result, the region has one of the finest healthcare systems in the world. Over the forecast period of 2018-2026, the Europe CIC drug market is predicted to rise at a CAGR of 8.96%.

The countries analyzed for this region include the United Kingdom, France, Italy, Spain, Germany and the rest of Europe. UK healthcare system is controlled by its medical arm known as NHS, i.e. National Health System, which is one of the largest healthcare systems present in the world. Germany is considered to have a mature market with high healthcare expenditure and pharmaceutical production, but its future growth could be potentially hindered by cost-saving government policies. The high unmet needs for the CIC conditions are chiefly providing the market with growth opportunities. However, some of the possible side effects of CIC drugs might prove challenging for the market growth.

The top players in the market include Theravance Biopharma Inc, Progenics Pharmaceuticals Inc, Cosmo Pharmaceuticals SA, Daiichi Sankyo Co Ltd, Valeant Pharmaceuticals International, Ironwood Pharmaceuticals Inc, Sucampo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Eli Lilly And Company, Merck Sharp & Dohme, Bayer Ag, Roche Holding Ag, GlaxoSmithKline, Pfizer, Synergy Pharmaceuticals, Ferring International Center S.A., Chugai Pharmaceutical, and Allergens.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - LINACLOTIDE MARKET TO WITNESS FASTEST GROWTH RATE DURING THE FORECAST PERIOD
  - OVER THE COUNTER SEGMENT TO HOLD MAJOR SHARE OF THE CIC DRUG MARKET BY PRESCRIPTION TYPE

MARKET OVERVIEW
- MARKET DEFINITION
- KEY MARKET INSIGHTS
- ATTRACTIVE INVESTMENT SCENARIO
- POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
- MARKET DRIVERS
  - MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
  - CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
  - INCREASING ELDERLY POPULATION
  - IMPROVED AND EFFICIENT DRUGS IN PIPELINE
  - INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
- RESTRAINTS
  - SURGICAL TREATMENTS
  - UNAWARENESS AND IGNORANCE AMONG PEOPLE
- OPPORTUNITIES
  - HIGH UNMET NEEDS
- CHALLENGES
  - SIDE EFFECTS OF CIC DRUGS

EUROPE CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
- OVERVIEW
  - LUBIPROSTONE
  - LINACLOTIDE
  - OTHERS
- PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLON)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
- PRESCRIBED DRUGS
- OVER THE COUNTER DRUGS
KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
  - INTENSITY OF COMPETITIVE RIVALRY
  - BARGAINING POWER OF SUPPLIERS
  - BARGAINING POWER OF BUYERS
  - THREAT OF SUBSTITUTE PRODUCTS
  - THREAT OF NEW ENTRANTS
- REGULATORY FRAMEWORK
- VENDOR LANDSCAPE
- OPPORTUNITY MATRIX
EUROPE CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
- UK
- GERMANY
- FRANCE
- ITALY
- SPAIN
- REST OF EUROPE
COMPANY PROFILES
- ALLERGENS
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- CHUGAI PHARMACEUTICAL
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- FERRING INTERNATIONAL CENTER S.A.
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- SYNERGY PHARMACEUTICALS
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- PFIZER
  - OVERVIEW
  - PFIZER PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- GLAXOSMITHKLINE
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- ROCHE HOLDING AG
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- SANOFI
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- BAYER AG
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- MERCK SHARP & DOHME
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- ELI LILLY AND COMPANY
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- SALIX PHARMACEUTICALS LTD
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- SUCAMPO PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- IRONWOOD PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- VALEANT PHARMACEUTICALS INTERNATIONAL
  - OVERVIEW
- DAIICHI SANKYO CO LTD
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- COSMO PHARMACEUTICALS SA
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- PROGENICS PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- THERAVANCE BIOPHARMA INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS

TABLE LIST

TABLE 1 EUROPE CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)

TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION

TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE

TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION

TABLE 5 EUROPE CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)

TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 7 PRODUCT PROFILE (LINACLOTIDE)

TABLE 8 PRODUCT PROFILE (BISACODYL)

TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 11 EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS

TABLE 13 EUROPE CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)

TABLE 14 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 15 UK CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)

TABLE 16 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 17 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)

FIGURE LIST

FIGURE 1 EUROPE CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 2 EUROPE CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)

FIGURE 3 EUROPE CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)

FIGURE 4 CAUSES OF CONSTIPATION

FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014

FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE

FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS

FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION

FIGURE 9 NEED OF SURGERY PROCESS

FIGURE 10 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM

FIGURE 11 EUROPE LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 12 EUROPE LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 13 EUROPE OTHER DRUGS MARKET 2018-2026 ($ MILLION)

FIGURE 14 EUROPE PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)

FIGURE 15 EUROPE OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 16 EUROPE CIC DRUGS MARKET 2018-2026 ($ MILLION)

FIGURE 17 UK CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 18 GERMANY CIC DRUG MARKET, 2018-2026 $ MILLION)

FIGURE 19 FRANCE CIC DRUG MARKET, 2018-2026 $ MILLION)

FIGURE 20 ITALY CIC DRUG MARKET, 2018-2026 $ MILLION)

FIGURE 21 SPAIN CIC DRUG MARKET, 2018-2026 $ MILLION)

FIGURE 22 REST OF EUROPE CIC DRUG MARKET 2018-2026 ($ MILLION)

Segmentation

EUROPE CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
- UK
- GERMANY
- FRANCE
- ITALY
- SPAIN
- REST OF EUROPE
EUROPE CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
- OVERVIEW
  - LUBIPROSTONE
  - LINACLOTIDE
  - OTHERS
- PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
- PRESCRIBED DRUGS
- OVER THE COUNTER DRUGS